When to use inj amikacin
Amikacin is an aminoglycoside antibiotic used primarily for serious gram-negative infections, especially when other aminoglycosides (gentamicin, tobramycin) have failed due to resistance. It covers organisms like Pseudomonas, Klebsiella, E. coli, Enterobacter, Acinetobacter, and Serratia.
Searching sources...
Reading File
Finding Sources
Searching the Web
amikacin injection indications clinical uses dosage
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
I now have comprehensive information from multiple authoritative sources. Here is a complete answer:
Injection Amikacin - When to Use
Class & Mechanism
Amikacin is a semisynthetic aminoglycoside antibiotic (derived from kanamycin). It works by:
- Binding the 30S ribosomal subunit and causing misreading of mRNA
- Concentration-dependent bactericidal killing (higher peak = greater kill rate)
- Significant post-antibiotic effect - antibacterial activity persists even after serum levels fall below MIC
Spectrum of Activity
| Organism | Susceptibility to Amikacin |
|---|---|
| E. coli | ~99% |
| Enterobacter spp. | ~100% |
| Pseudomonas aeruginosa | ~98% |
| Serratia spp. | ~99% |
| Klebsiella spp. | ~88% |
| Acinetobacter baumannii | ~58% |
Key advantage over gentamicin/tobramycin: Amikacin is resistant to most aminoglycoside-modifying enzymes, so gram-negative bacteria that are gentamicin-resistant are often still susceptible to amikacin. This makes it the preferred aminoglycoside for multi-drug-resistant organisms.
Does NOT cover: Anaerobes, Stenotrophomonas maltophilia, Burkholderia cepacia.
Clinical Indications
1. Serious Gram-Negative Infections (Primary Use)
- Septicemia / bacteremia - especially gram-negative bacteremia
- Hospital-acquired pneumonia (HAP) / ventilator-associated pneumonia (VAP) - particularly when Pseudomonas or resistant gram-negatives are involved
- Intra-abdominal infections (peritonitis, post-operative infections) - usually in combination with metronidazole or a beta-lactam
- Urinary tract infections - complicated UTIs and recurrent UTIs not susceptible to other antibiotics; uncomplicated UTI dose: 250 mg IV/IM twice daily
- Skin & soft tissue infections - including burns and wound infections
- Bone & joint infections (osteomyelitis caused by gram-negatives)
2. CNS Infections
- Meningitis from gram-negative rods - e.g., after penetrating head trauma (S. aureus, gram-negative rods); combined with vancomycin + cefepime/meropenem
- Intraventricular/intrathecal amikacin for refractory gram-negative meningitis when IV levels are subtherapeutic in CSF
3. Neonatal Sepsis
- One of the standard agents for early and late-onset neonatal sepsis (often combined with ampicillin or a beta-lactam)
4. Mycobacterial Infections
- Tuberculosis (MDR-TB / XDR-TB) - second-line agent used in combination regimens
- Nontuberculous mycobacteria (NTM) - active against M. avium complex (MAC) and M. abscessus; may substitute streptomycin in M. xenopi regimens
5. Multidrug-Resistant (MDR) Gram-Negatives
- When gentamicin/tobramycin resistance is documented, amikacin is the aminoglycoside of choice
- Active against many ESBL-producing and some carbapenem-resistant Enterobacterales (CRE) when other agents are exhausted
6. Synergistic Combinations
- Combined with beta-lactams or vancomycin against:
- P. aeruginosa infections (synergistic combination standard of care)
- Gram-positive endocarditis (gentamicin preferred, but amikacin used if resistant)
- Enterococcal infections (enhances cell wall-active agents)
Dosage
| Patient | Dose |
|---|---|
| Adults (general) | 15 mg/kg/day IV/IM in 2-3 divided doses (7.5 mg/kg q12h or 5 mg/kg q8h); max 1.5 g/day |
| Once-daily (extended interval, preferred) | 15 mg/kg IV once daily |
| Uncomplicated UTI | 250 mg IV/IM q12h |
| Duration | 7-10 days typically; adjust based on response |
Extended-interval (once-daily) dosing is now preferred for most indications and patient populations - it is at least equally efficacious and potentially less toxic than divided dosing, due to the concentration-dependent killing and post-antibiotic effect.
Monitoring (Therapeutic Drug Monitoring)
- Peak (30-90 min after infusion): target 20-35 mcg/mL; avoid >35 mcg/mL
- Trough (just before next dose): keep <10 mcg/mL to reduce nephrotoxicity
- Renal function (BUN, creatinine) monitored throughout therapy
Important Adverse Effects
- Nephrotoxicity - usually reversible; risk increases with duration and co-use of other nephrotoxic drugs (NSAIDs, vancomycin, contrast)
- Ototoxicity - can be irreversible; affects both auditory (hearing loss) and vestibular function (via 8th CN)
- Dose adjustment mandatory in renal impairment
Contraindications / Cautions
- Pre-existing renal impairment (use with dose adjustment only)
- Pregnancy (late pregnancy - accumulates in fetal kidneys; aminoglycosides are ototoxic to the fetus)
- Caution with concurrent neuromuscular blocking agents, anesthetics, and other nephrotoxic drugs
In summary, inject amikacin when you need bactericidal gram-negative coverage for serious infections, especially in hospital/ICU settings, when resistance to other aminoglycosides is likely, or when treating MDR organisms or mycobacterial disease.
- Goodman & Gilman's Pharmacological Basis of Therapeutics, 13e, p. 1189-1200
- Harrison's Principles of Internal Medicine, 22e, p. 1220
- Katzung's Basic & Clinical Pharmacology, 16e, p. 544
This is a shared conversation. Sign in to Orris to start your own chat.